SPY -0.17%
BND +0.22%
QQQ +1.68%
DIA -2.11%
VNQ -1.28%
GLD -3.54%
BTC -2.03%
AAPL +0.26%
GOOGL +3.42%
NVDA -2.03%
MSFT -0.74%
META -0.24%
AMZN +6.18%
TSLA +2.90%
UBER -0.81%
GS -0.40%
BAC -1.47%
JPM -3.39%
BRK.A -2.71%
COST -2.02%
XOM -3.76%
BABA -8.74%
WMT -1.51%
SPCX +6.80%
DIS +2.80%
F -1.64%
  • Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Top Stories
A Wegovy package is captured with a scale in the background. Michael Siluk/UCG/Universal Images Group via Getty Images

‘Will these kids wind up shorter?’: Ohio teen lost 100 pounds on a GLP-1. Now a study shows benefits for ages 6 to 11 — but at what cost?

A new study found that Wegovy helped obese children as young as six years old with losing weight. However, the children who took the drug also grew more slowly than those who received a placebo.

In the STEP Young trial, funded by Novo Nordisk, body mass index (BMI) for those in the Wegovy group fell by an average of 13.5% after 68 weeks, but for those in the placebo group, BMI rose by an average of 2.7%. Over two years, the median height gain was about three and a half inches for those in the Wegovy group and nearly five inches for those in the placebo group.

Advertisement

It’s still unclear whether that difference will affect how tall the children will become as adults.

The money news that actually matters.

By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.

“Will these kids wind up shorter? I don’t know. Is that a big deal for these kids? I don’t know. But those are the types of things I worry about,” Dr. Robert Siegel, an obesity-medicine pediatrician at Cincinnati Children’s Hospital, told The Wall Street Journal.

In a statement to Moneywise, a Novo Nordisk spokesperson said children with obesity can grow faster before puberty and suggested the slower growth in the Wegovy group may reflect a return to a more typical growth rate as their BMI fell.

“Importantly, the STEP Young trial was not designed or powered to draw conclusions about effects on growth, so the study does not establish what these findings may mean for children’s long-term growth,” the spokesperson said, adding that injectable semaglutide use is still being studied in children under 12.

Will insurance cover treatment?

Among teens, GLP-1 drugs are becoming more common, though insurance gaps can make it hard to stay on treatment. That’s what Nicholas Hackenburg found when he started taking the drug.

Growing up, Hackenburg heard the same advice over and over: “eat less and move more.” The 17-year-old high school senior from Clyde, Ohio, played sports and tried different diets. When he did lose weight, it usually came back within a few months, according to The Wall Street Journal.

His struggle is one that many families face. Roughly 21% of American children and adolescents between the ages of two to 19 have obesity, according to CDC data collected between August 2021 and August 2023.

Genetic testing later helped explain why Hackenburg had developed severe obesity so young. He started taking GLP-1 drugs several years ago, but changes in his insurance coverage made it hard to stay on them.

That’s a struggle many Americans face when accessing GLP-1s. Coverage depends on the plan, according to Dr. Amy Rapaport, medical director at Hey Nouri, and Dr. Anna Trepekli, the company’s co-founder. Some insurers require prior authorization, while others exclude obesity medications altogether, they told Moneywise in shared written responses.

Advertisement

“In our experience at Hey Nouri, about 60% of children who meet their plan’s criteria get approved, sometimes after an appeal, and we handle all of that for the family,” the doctors said. “Families who get coverage typically have a small copay.”

Must Read

What parents should know

When Hackenburg was on the medication, he experienced some side effects as his dose increased. But after 11 months of uninterrupted treatment, he lost roughly 100 pounds.

He’s among the nearly 31,000 Americans between the ages of 12 and 17 who filled a GLP-1 prescription in 2023, according to a study published in JAMA Network. That figure includes prescriptions for both diabetes and weight management.

For parents who already have to weigh the cost and possible side effects of these drugs, the STEP Young trial’s findings on growth give them one more thing to consider. Rapaport and Trepekli say the risks of leaving obesity untreated should be part of that decision, too.

Advertisement

“Every medication has side effects, and they have to be weighed against the risk of not treating [obesity],” they told Moneywise.

GLP-1s aren’t appropriate or necessary for every child, they added. For those who take them, doctors need to closely monitor their nutrition, growth, side effects and how quickly they lose weight.

“Kids aren’t mini adults, so children on these medications need more monitoring than adults,” Rapaport and Trepekli added.

Before getting started, the doctors recommend asking who will follow the child’s growth, check that they’re getting enough nutrition and help if side effects make eating or drinking difficult. Parents should also ask what support comes with the prescription, including help with nutrition, activity and emotional well-being. Those conversations should focus on what matters to the child, such as having more energy for sports or feeling comfortable spending time with friends.

“The most important thing is that medication is not used in isolation,” Rapaport and Trepekli said. “It is one part of treatment.”

You May Also Like

Share this:
Victoria Vesovski Senior Reporter

Victoria Vesovski is a Toronto-based staff reporter at Moneywise covering personal finance, lifestyle and trending news. She holds degrees from the University of Toronto and New York University, and her work has appeared on platforms including Yahoo Finance, MSN Money and Apple News.

more from Victoria Vesovski

Explore the latest

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither investment, tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities, enter into any loan, mortgage or insurance agreements or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter. Advertisers are not responsible for the content of this site, including any editorials or reviews that may appear on this site. For complete and current information on any advertiser product, please visit their website.

†Terms and Conditions apply.